Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 72
Filtrar
1.
Dermatol Surg ; 2024 Oct 16.
Artículo en Inglés | MEDLINE | ID: mdl-39412146

RESUMEN

BACKGROUND: Mohs micrographic surgery (MMS) offers high cure rates for nonmelanoma skin cancer (NMSC) but relies on precise margin assessment, traditionally initiated by the naked eye. Dermoscopy has emerged as a potential tool to improve margin delineation. OBJECTIVE: To compare the efficacy of dermoscopic versus naked eye evaluation in marking initial MMS margins for NMSC. METHODS: A multicenter, prospective study on patients with NMSC undergoing MMS was conducted. Patients were randomized into dermoscopy and naked eye groups. Statistical analysis was performed using statistical package for social sciences. RESULTS: A total of 127 patients were enrolled, with 63 in the naked eye group and 64 in the dermoscopy group. No significant differences in age, sex distribution, or histological subtype were found. The average number of MMS stages and accuracy of initial margins were comparable between groups. DISCUSSION: Despite its potential, the authors' study found no significant reduction in total MMS stages using dermoscopy. Novel imaging modalities or standardized dermoscopic criteria should be explored to enhance margin assessment accuracy and improve outcomes in NMSC treatment. CONCLUSION: Dermoscopic evaluation of presurgical margins does not effectively assess lateral/deep margins nor contribute to a reduction in total MMS stages. Improving the authors' understanding of presurgical margin assessment techniques can lead to better treatment outcomes for NMSC.

2.
J Am Acad Dermatol ; 2024 Sep 07.
Artículo en Inglés | MEDLINE | ID: mdl-39182674

RESUMEN

BACKGROUND: Vitiligo lesions are often challenging to repigment with conventional medical therapies. Surgical autologous melanocyte transfer methods can be utilized for stable vitiligo but demand specialized skills and equipment. A point-of-care autologous cell harvesting device was designed enabling simple preparation of autologous skin cell suspension (ASCS) containing melanocytes, keratinocytes, and fibroblasts providing a straightforward approach for cellular transplantation. OBJECTIVE: To evaluate the safety and effectiveness of ASCS for repigmentation of stable vitiligo lesions among adults. METHODS: A US multicenter, randomized, within-subject controlled trial compared ASCS to narrow band ultraviolet B only (Control) in similar vitiligo lesions. ASCS was applied after laser skin resurfacing and followed by narrow band ultraviolet B treatment. The primary effectiveness endpoint was the proportion of lesions achieving ≥80% repigmentation at week-24. Repigmentation durability was assessed at week-52. RESULTS: Among 25 subjects, 36% of ASCS-treated lesions achieved ≥80% repigmentation at week-24 compared to 0% for Control (P < .025), with durability through week-52. The safety profile of ASCS was acceptable, with favorable patient- and investigator-reported outcomes. LIMITATIONS: Study sample size limited robust subgroup analyses. CONCLUSION: Application of ASCS has potential as a treatment for repigmentation of stable vitiligo lesions with the potential to improve health-related quality of life and reduce burden of disease.

4.
J Clin Aesthet Dermatol ; 17(4): 6-7, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-38638187
5.
Dermatol Reports ; 15(2): 9614, 2023 Jun 07.
Artículo en Inglés | MEDLINE | ID: mdl-37397403

RESUMEN

Treatment of disseminated granuloma annulare (GA) can be challenging and there is no gold standard for treatment. We observed two cases of generalized GA that were treated successfully with canary seed milk despite being resistant to other treatments. Canary seed milk has antioxidant (contains vitamin E), anti-diabetic (DPP-4 inhibition), and anti-hypertensive (ACE inhibition) properties. Therefore, dermatologists can consider canary seed milk, also known as alpiste milk, as a sole or supplemental treatment for patients with GA with or without comorbidities such as diabetes and hypertension, who prefer alternative therapy or failed other treatments.

6.
J Clin Aesthet Dermatol ; 16(5): 47-49, 2023 May.
Artículo en Inglés | MEDLINE | ID: mdl-37288279

RESUMEN

Background: Both onabotulinumtoxinA and prabotulinumtoxinA-xvfs are FDA-approved formulations of botulinum toxin A for the treatment of glabella and forehead rhytids. Objective: We sought to compare the onset to action and patient satisfaction of onabotulinumtoxinA and prabotulinumtoxinA-xvfs in treating dynamic rhytids of the forehead and glabella. Methods: Fifteen patients, aged 28 to 74, were enrolled and completed the study. Patients were randomly assigned to receive equal amounts of onabotulinumtoxinA and prabotulinumtoxinA-xvfs injected to opposite sides of the face in the glabella and forehead at Day 0 by a blinded injector. Glabellar and frontalis muscle onset to action and rhytid appearance were blindly evaluated using photographs at Days 0, 2, 4, 6, 8, 10 post-injection. Patients rated their satisfaction of left and right sides using a standardized scale. Results: There was no statistically significant difference in onset to action, rhytid appearance, and patient satisfaction after injection with onabotulinumtoxinA versus prabotulinumtoxinA-xvfs in the corrugator and frontalis muscles. Although not statistically significant, a trend existed towards increased patient satisfaction with onabotulinumtoxinA. Conclusion: Both onabotulinumtoxinA and prabotulinumtoxinA-xvfs are equally efficacious formulations of botulinum toxin type A for the treatment of glabellar and forehead rhytids.

8.
J Cosmet Dermatol ; 22(4): 1261-1265, 2023 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-36756716

RESUMEN

BACKGROUND: Laser has been long accepted as a solution for excess or unwanted hair growth yet traditional lasers are not always ideal for safe and effective outcome for all skin types and hair characteristics. A diode laser module combining three wavelengths (755, 810, and 1064 nm) in a single pulse was developed to provide a fast and long-term solution for subjects with various profiles. AIMS: To evaluate the safety and efficacy of a Triple wavelength diode laser module for hair removal treatment in all skin types (Fitzpatrick I-VI). SUBJECTS AND METHODS: This was a prospective, dual centered, single-arm study. Subjects were treated with a novel diode laser module. Thirty-six subjects were enrolled, sixteen with Fitzpatrick skin types I-IV (46%) and twenty with Fitzpatrick skin types V-VI (54%). Treatment areas were axilla and bikini lines. Subjects underwent 4 treatment sessions at 6 weeks ± 5 days intervals and attended a follow-up visit 3 months after the last treatment session. 2D digital photographs were taken at baseline and at the follow-up visit, and a hair count was conducted by three blinded evaluators. RESULTS: A significant reduction in hair count between baseline and the 3-month follow-up visit was observed in both axilla and bikini lines for all skin types. The mean hair reduction was 41.5 ± 19.4% and 48.1 ± 20.9% in the axilla and bikini line, respectively. A significant hair reduction was also observed within skin type groups; mean hair reduction 45.5 ± 16.9% and 40.3 ± 17.2% in skin types I-IV and V-VI, respectively, indicating similar efficacy for both light and dark skin types. No serious adverse events were reported. CONCLUSIONS: This study demonstrates that the Soprano Titanium laser platform is safe and effective for hair removal treatment in all skin types.


Asunto(s)
Remoción del Cabello , Terapia por Luz de Baja Intensidad , Pigmentación de la Piel , Humanos , Cabello , Remoción del Cabello/efectos adversos , Remoción del Cabello/métodos , Láseres de Semiconductores/efectos adversos , Láseres de Semiconductores/uso terapéutico , Estudios Prospectivos , Resultado del Tratamiento , Terapia por Luz de Baja Intensidad/efectos adversos , Terapia por Luz de Baja Intensidad/métodos , Axila , Abdomen , Pigmentación de la Piel/efectos de la radiación , Quemadura Solar/etiología , Bronceado/efectos de la radiación
9.
Cutis ; 110(4): E27-E29, 2022 10.
Artículo en Inglés | MEDLINE | ID: mdl-36446105
12.
J Cosmet Dermatol ; 21(12): 6698-6701, 2022 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-36106510

RESUMEN

BACKGROUND: Laser hair reduction is a common practice that utilized light-based therapy to prevent future hair growth. Complications following laser hair reduction treatment include thermal burns, which may lead to hyper- or hypopigmentation, hair stimulation, scar, or transient erythema of treated areas. AIMS: Review reports of persistent urticaria following laser hair reduction and discuss a rarely discussed laser complication. METHODS: Pubmed literature review. RESULTS: There have been very rare reports of persistent urticaria following laser hair reduction. Similar case reports have also been described though no definitive reasoning for this reaction, nor consistent treatment has been documented. DISCUSSION: In this report, we present a patient who developed persistent urticaria with severe pruritus in the areas treated with laser hair reduction. Previous reports an association was found between allergies and post-treatment urticarial eruption, with 33/36 patients having allergies, mostly to dust mites which is similar to the patient presented. Other etiologies such as reaction to cryogen and physical urticaria are unlikely. CONCLUSION: Our report highlights a case of persistent urticaria with severe pruritus following laser hair reduction treatment, with both similarities and differences to other cases reported in the literature. While this is a rare side effect of laser hair removal, it should be monitored in patients who have a history of moderate to severe environmental allergies.


Asunto(s)
Remoción del Cabello , Terapia por Láser , Urticaria , Humanos , Urticaria/etiología , Urticaria/tratamiento farmacológico , Remoción del Cabello/efectos adversos , Rayos Láser , Cabello , Prurito/etiología , Terapia por Láser/efectos adversos
14.
J Drugs Dermatol ; 20(9): 970-978, 2021 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-34491024

RESUMEN

BACKGROUND: Eyebrow rejuvenation is a common cosmetic concern among patients presenting to dermatologists. Due to increased patient demand for non-invasive procedures, multiple non-surgical, and minimally invasive eyebrow rejuvenation techniques have been developed. OBJECTIVE: This review aims to highlight the various non-surgical eyebrow rejuvenation therapeutic techniques described in the medical literature. Methods & Materials: A review of published articles on non-surgical and minimally invasive eyebrow rejuvenation using neurotoxins, fillers, lasers, threads, bimatoprost solution, and tattooing was conducted using the PubMed database. RESULTS: Currently available non-surgical options for eyebrow rejuvenation include neuromodulators, fillers, laser resurfacing, radiofrequency, and minimally invasive procedures such as tattooing and brow lift using threading. CONCLUSION: The eyebrow is a complex and dynamic region. A thorough understanding of the anatomy of the supraorbital region and familiarity with available, minimally invasive treatment options is essential to tailor an individualized approach consisting of one or more treatments to achieve optimal rejuvenation outcomes. J Drugs Dermatol. 2021;20(9):970-978. doi:10.36849/JDD.6188.


Asunto(s)
Técnicas Cosméticas , Ritidoplastia , Envejecimiento de la Piel , Cejas , Humanos , Rejuvenecimiento
16.
Am J Dermatopathol ; 43(4): 291-293, 2021 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-33464751

RESUMEN

ABSTRACT: The pathophysiology of melanoma involves malignant transformation of melanocytes. These can arise de novo or result from malignant transformation of a pre-existing nevus. This case report presents a patient with a new pigmented lesion, arising from a pre-existing neurofibroma, on her left scapula and no personal or family history of systemic neurofibromatosis. Biopsy confirmed the lesion to be malignant melanoma and, after excision, postoperative pathology showed a pre-existing neurofibroma. A review of the literature suggests there may be a link between the pathogenesis of neurofibroma and malignant melanoma, because NF1 mutations are observed in both neurofibromatosis and malignant melanoma. We hypothesize that the pre-existing neurofibroma created a proliferative environment that gave rise to the adjacent neoplasm. Further research is required to understand the shared pathway, because this may lead to novel forms of surveillance and treatment.


Asunto(s)
Melanoma/patología , Neurofibroma/patología , Neoplasias Cutáneas/patología , Anciano de 80 o más Años , Biopsia , Proliferación Celular , Femenino , Humanos , Melanoma/cirugía , Neurofibroma/cirugía , Neoplasias Cutáneas/cirugía
17.
JAAD Case Rep ; 6(10): 1024-1026, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-32995436
18.
J Clin Aesthet Dermatol ; 13(1): 35-37, 2020 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-32082470

RESUMEN

Acral myxoinflammatory fibroblastic sarcoma (AMFS) represents a low-grade sarcoma with a high rate of local recurrence that commonly affects the distal extremities. The lesion often presents as a painless mass in the hands or feet. There is no formal standardized treatment protocol for this tumor, but wide surgical excision, with or without adjuvant radiation therapy, is the conventional treatment. We report a case of a patient with an AMFS treated with Mohs micrographic surgery (MMS) without recurrence. Because of the propensity of this tumor to involve acral sites where tissue conservation is important, MMS might be an alternative treatment modality for this rare entity.

19.
J Clin Aesthet Dermatol ; 13(10): 12-16, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-33584951

RESUMEN

BACKGROUND: Surgical treatment of keloid scars is associated with an approximately 70% recurrence rate at the excision site. OBJECTIVE: We sought to assess keloid recurrence rates when superficial radiation therapy (SRT) was applied following surgical excision. METHODS: Medical records were reviewed of subjects treated for keloid scars followed by SRT (SRT-100™; Sensus Healthcare, Boca Raton, Florida) using a biologically effective dose (BED) of 30Gy and for whom the required retrospective data was available. Eligible subjects (N=61) were treated for 96 keloid scars with SRT. Subjects were male (48%) and female (52%) with a mean age of 38.87 years. Subjects were treated for ≥1 keloid scars following removal by sutured excision (93%) or tangential excision with secondary intention technique (7%). Almost all subjects (98%) received BED 30Gy with irradiation scheme of three 6Gy SRT treatments on Days 1, 2 and 3 following surgery. Mean energy of 100KV (73%) or 70KV (27%) were applied. RESULTS: Ten treated keloidectomy sites (10.4%) had recurrences (i.e., presence of any new tissue growth on the surgical scar) within 12 months increasing to 11 (12.7%) at 18 months. Kaplan-Meier survival probability cure rate was 85.6% from 24 months post-SRT treatment onwards. Transient hyperpigmentation was the most frequent adverse event and there were no malignancies in the treatment area during follow-up evaluations. CONCLUSIONS: SRT with a BED value of 30 Gy delivered to keloidectomy excision sites immediately following excision was well-tolerated and resulted in markedly fewer long-term recurrences than reported following keloidectomy alone. Most keloid scar recurrences occurred within one year. There were no malignancies during follow-up evaluations.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...